EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium

Esther N Dekker iD, David van Klaveren iD, Eva M M Verkolf iD, Roeland F de Wilde, Marc G Besselink iD, Eileen M O'Reilly, Alessandro Paniccia iD, Alice C Wei iD, Amer H Zureikat iD, Laura R Prakash iD, Matthew H G Katz iD, Ching-Wei D Tzeng iD und 2 weitere

JNCI: Journal of the National Cancer Institute · 2026

DOI: 10.1093/jnci/djag024 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Esther N Dekker und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hendrik Muller Foundation, Onno Ruding Foundation, Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Restaging after neoadjuvant chemotherapy aims to assess treatment response, revise prognosis, and guide further management. This study investigated independent prognostic factors for overall survival after restaging in patients with localized pancreatic adenocarcinoma.

Methods

In this retrospective international study, consecutive patients with localized pancreatic adenocarcinoma who received at least 1 cycle of (m)FOLFIRINOX as first-line therapy were identified. Multivariable Cox regression analysis was performed with a web-based calculator to predict individualized overall survival.

Results

The Trans-Atlantic Pancreatic Surgery cohort included 2338 patients with localized pancreatic adenocarcinoma of whom 22.6% were potentially resectable, 30.7% borderline resectable, and 46.7% locally advanced at initial staging. Several baseline characteristics remained independent prognostic factors for overall survival after restaging: borderline resectable (hazard ratio [HR] = 1.31, 95% confidence interval [CI] = 1.14 to 1.51), locally advanced (HR = 1.78, 95% CI = 1.55 to 2.05), body or tail tumor (HR = 0.79, 95% CI = 0.68 to 0.90), and baseline World Health Organization performance status of 1 (HR = 1.18, 95% CI = 1.07 to 1.30) or at least 2 (HR = 1.54, 95% CI = 1.20 to 1.98). Additional independent factors were metastatic disease at restaging (HR = 1.57, 95% CI = 1.31 to 1.87), postinduction carbohydrate antigen 19-9 (HR = 1.47, 95% CI = 1.37 to 1.57), Δcarbohydrate antigen 19-9 (HR = 0.83, 95% CI = 0.77 to 0.89), postinduction tumor size (HR = 1.22, 95% CI = 1.11 to 1.35), and Δtumor size (HR = 0.92, 95% CI = 0.87 to 0.98). Patients were stratified into 4 risk groups, with 3-year overall survival after restaging ranging from 6.0% to 65.8%.

Conclusion

Survival at restaging after neoadjuvant chemotherapy of patients with localized pancreatic adenocarcinoma is determined by 8 patient, tumor, and treatment response characteristics. A web-based calculator can inform clinicians and patients about individualized prognosis and guide further management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAdenocarcinomaHumansNeoadjuvant TherapyFemaleRetrospective StudiesMaleAgedNeoplasm StagingIrinotecanMiddle AgedLeucovorinOxaliplatinFluorouracilPrognosisCA-19-9 AntigenPancreatectomy

Substanzen

IrinotecanLeucovorinfolfirinoxOxaliplatinFluorouracilCA-19-9 Antigen

Autor:innen und Institutionen

  • Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Public Health, Center for Medical Decision Making, Erasmus MC, Rotterdam, the Netherlands.
  • Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

ORCID-Profile: Esther N Dekker, David van Klaveren, Eva M M Verkolf, Marc G Besselink, Alessandro Paniccia, Alice C Wei, Amer H Zureikat, Laura R Prakash, Matthew H G Katz, Ching-Wei D Tzeng, Bas Groot Koerkamp

Förderung

  • Hendrik Muller Foundation
  • Onno Ruding Foundation
  • Dutch Cancer Society
  • NCI NIH HHS
  • Fulbright Foundation
  • Crone-Haver Droeze Foundation

Zitieren

APA

Dekker, E. N., van Klaveren, D., Verkolf, E. M. M., de Wilde, R. F., Besselink, M. G., O'Reilly, E. M., Paniccia, A., Wei, A. C., Zureikat, A. H., Prakash, L. R., Katz, M. H. G., Tzeng, C. D., Groot Koerkamp, B., & Trans-Atlantic Pancreatic Surgery Consortium (2026). Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag024

Vancouver

Dekker EN, van Klaveren D, Verkolf EMM, de Wilde RF, Besselink MG, O'Reilly EM, et al. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djag024

BibTeX
@article{Dekker2026,
  author = {Dekker, Esther N and van Klaveren, David and Verkolf, Eva M M and de Wilde, Roeland F and Besselink, Marc G and O'Reilly, Eileen M and Paniccia, Alessandro and Wei, Alice C and Zureikat, Amer H and Prakash, Laura R and Katz, Matthew H G and Tzeng, Ching-Wei D and Groot Koerkamp, Bas and Trans-Atlantic Pancreatic Surgery Consortium, Trans-Atlantic Pancreatic Surgery Consortium},
  title = {Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  doi = {10.1093/jnci/djag024}
}
Kostenlos starten →